Key result
In a Russian registry of 6,255 outpatients with chronic heart failure, 42.4% had HFrEF, 43.2% had chronic kidney disease, and prescription of optimal quadruple therapy for HFrEF was insufficient.
Why the study?
Demographic and clinical laboratory characteristics, concomitant diseases, and drug therapy of outpatients with heart failure in the Russian Federation needed to be described.
Observational (n=6,255)
Yes
Answers are grounded in this paper and cite their sources.
Characterizes Russian HF outpatients; leaves open whether local care aligns with guidelines or improves outcomes.
Aim. To describe demographic and clinical laboratory characteristics, concomitant diseases and drug therapy of outpatients with heart failure (HF) in the Russian Federation. Material and methods. An interim analysis of a prospective observational multicenter registry study of patients with chronic heart failure in the Russian Federation ("PRIORITET-CHF") was performed. The study included outpatients with HF followed by a general practitioner or cardiologist. Results. Data from 6255 patients were analyzed (31,3% of the study sample; median age, 65 years; men, 65%). HF with reduced ejection fraction (HFrEF) was diagnosed in 42,4%, HF with preserved EF — in 31,9%. In addition, 57,4% of patients were characterized by NYHA class II HF. The most common causes of HF were hypertension, coronary artery disease, and atrial fibrillation or flutter. Of the concomitant diseases, doctors most often reported chronic kidney disease (CKD) (43,2%), obesity (37,8%) and diabetes (26,7%) in HF. Conclusion. In the Russian Federation, among outpatients with HF, there was domination of men, HFrEF phenotype, NYHA class II. The relatively young mean age and frequent associations of HF with cardiovascular risk factors and diseases underscore the importance of timely prevention initiatives. The identified high proportion of patients with CKD requires special attention and separate analysis. Despite the relatively high prescription rate of certain classes of diseasemodifying therapy for HF, the prescription of optimal quadruple therapy and electrophysiological treatments for HFrEF is insufficient.
No takes yet. Share an insight, caveat, or question.
Shlyakhto et al. (2023) conducted an observational in chronic heart failure (n=6,255). Chronic heart failure was evaluated on Demographic and clinical characteristics, concomitant diseases, and drug therapy. In a Russian registry of 6,255 outpatients with chronic heart failure, 42.4% had HFrEF, 43.2% had chronic kidney disease, and prescription of optimal quadruple therapy for HFrEF was insufficient.
Synapse has enriched 10 related papers. Consider them for comparative context: